AtriCure, Inc. (ATRC) CFO Sells $36,820.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) CFO M. Andrew Wade sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total transaction of $36,820.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

AtriCure, Inc. (NASDAQ:ATRC) opened at $18.52 on Monday. AtriCure, Inc. has a 1-year low of $14.78 and a 1-year high of $25.18. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The business had revenue of $42.20 million for the quarter, compared to analyst estimates of $43.44 million. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The company’s revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.21) EPS. equities analysts forecast that AtriCure, Inc. will post -0.96 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE increased its position in AtriCure by 152.1% during the 2nd quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock worth $102,000 after purchasing an additional 2,535 shares in the last quarter. Sei Investments Co. increased its position in AtriCure by 75.5% during the 2nd quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock worth $168,000 after purchasing an additional 2,983 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in AtriCure during the 3rd quarter worth approximately $205,000. Legal & General Group Plc increased its position in AtriCure by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock worth $208,000 after purchasing an additional 312 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in AtriCure during the 2nd quarter worth approximately $253,000. 86.17% of the stock is owned by hedge funds and other institutional investors.

ATRC has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. ValuEngine cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Canaccord Genuity lowered their price target on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. Needham & Company LLC lowered their price objective on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. Finally, TheStreet cut shares of AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. AtriCure has a consensus rating of “Hold” and an average target price of $25.00.

WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://ledgergazette.com/2017/12/04/atricure-inc-atrc-cfo-sells-36820-00-in-stock-2.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply